HuaLei Zhang1, Hui Qiao1,
Nataliya Petrenko2, Vickas Patel2, Bin Huang3,
Kenneth Boheler4, Victor Ferrari2, Rong Zhou1
1Department of Radiology, University of
Pennsylvania, Philadelphia, PA, United States; 2Dept of
Medicine(cardiovascular), University of Pennsylvania; 3Department
of Radiology, University of Pennsylvania, PA; 4National Institute
of Aging, NIH
Highly
enriched embryonic stem cell derived cardiomyocytes (ESC-CMs) were obtained
in large numbers for in vivo study that examined the potential of these cells
in the treatment of myocardial infarction. Our data suggest that ESC-CM
mediated a teratoma free myocardial repair with significant recovery of
regional and global contractile function over the period of 2 months.